ライフサイエンスコーパス: cell surface antigen

1 roteins, LAT2 and the heavy chain of the 4F2 cell surface antigen.

2 zation of a heretofore uncharacterized human cell surface antigen.

3 es than unconjugated mAbs targeting the same cell surface antigen.

4 eric antigen receptors (CARs) for a specific cell-surface antigen.

5 election of panels of specific antibodies to cell surface antigens.

6 glycosylphosphatidylinositol (GPI)-anchored cell surface antigens.

7 n D in conjunction with the dual staining of cell surface antigens.

8 glycosylphosphatidylinositol (GPI)-anchored cell surface antigens.

9 dentify Fabs selectively reactive with tumor cell surface antigens.

10 xpression of c mu, myeloid, erythroid, and T-cell surface antigens.

11 f cells with concurrent immunophenotyping of cell surface antigens.

12 d by loss of immune tolerance to nuclear and cell surface antigens.

13 nd nearby genes also encoding immunodominant cell surface antigens.

14 to trigger the expression of ICAM-1 and CD40 cell surface antigens.

15 ge, multi-copy gene families that encode red cell surface antigens.

16 cal model of multivalent antibody binding to cell surface antigens.

17 changes in their morphology or expression of cell surface antigens.

18 hibited monoclonal antibody binding to key T-cell surface antigens.

19 of antibodies that bound to prostate cancer cell surface antigens.

20 of radioimmunotherapy by targeting other NHL cell surface antigens.

21 s are primarily defined by the expression of cell-surface antigens.

22 GE-A3 pulsing on DC phenotypic expression of cell-surface antigens.

23 ed cultures with >400 antibodies recognizing cell-surface antigens.

24 f fully human monoclonal antibodies to B-CLL cell-surface antigens.

25 Using the MAb 2117, the cell surface antigen 2117 (Ag 2117) was cloned.

26 or the discovery of Fabs reactive with novel cell surface antigens a phage-expressed human antibody l

27 otpourri of complex target molecules such as cell surface antigens, allergens, and food contaminants.

28 onoclonal antibodies targeting neuroblastoma cell surface antigens and attached cells were removed us

29 othelioma-associated, clinically represented cell surface antigens and further exploited the internal

30 d, in principle, serve as superior mimics of cell surface antigens and hence, as multifaceted cancer

31 t of targeted biologics that recognize tumor cell surface antigens and of specific inhibitors of path

32 d, in principle, serve as superior mimics of cell surface antigens and, hence, as potent cancer vacci

33 er inputs: the simultaneous expression of a (cell surface) antigen and secreted enzyme to generate fu

34 nfirms and extends reports of alterations in cell-surface antigens and drug sensitivity correlated wi

35 tibody to gamma-sarcoglycan, a cardiomyocyte cell surface antigen, and mixed with freshly isolated ne

36 rotein belonging to the Ly-6/Thy-1 family of cell surface antigens, and a murine homologue has been d

37 lyclonal, recognizing both intracellular and cell surface antigens, and HSP60 was identified as one c

38 ies bound both yeast-displayed and mammalian cell surface antigens, and were endocytosed upon binding

39 s of neurons express distinct complements of cell-surface antigens, and that the regulation of CSPG e

40 By targeting internalizing cell surface antigens, antibody-siRNA complexes provide

41 f eight was initially selected from 95 human cell surface antigens as each was shared among human ova

42 as measured by expression of CD11b and CD66b cell surface antigens, as well as reduction of nitroblue

43 lobulin G and M antibodies against different cell surface antigens, but not to antibody-dependent cel

44 vidual backcross mice were also examined for cell surface antigen by fluorescence-activated cell sort

45 neth cells respond to bacteria and bacterial cell surface antigens by discharging secretory granules

46 bodies that recognized senescence-associated cell-surface antigens by FACS analysis and a newly devel

47 Initially, the loss of a cell-surface antigen can occur due to drift in isolated

48 eisserial lipooligosaccharide (LOS), a major cell-surface antigen, can be correlated with inflammator

49 Expression of the cell-surface antigen CD10 has long been used to define t

50 methylation pattern for one such marker, the cell surface antigen CD133 (Prominin 1).

51 de (LPS), LPS-binding protein (LBP), and the cell surface antigen CD14.

52 b, a monoclonal antibody which targets the B cell surface antigen CD20 and results in a rapid and sus

53 In resting cells the B-cell surface antigen CD20 is associated with the BCR but

54 herapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treat

55 itive and specific detection of a variety of cell surface antigens (CD3, CD20, and epithelial membran

56 The cell surface antigens CD33 and CD45 are attractive targe

57 ed hematopoietic precursor cells express the cell surface antigen CD34 and the hematopoietic transcri

58 uced maturation protein-1 (BLIMP-1), and the cell surface antigens CD38 and CD138/Syndecan-1.

59 is mainly mediated through ligation of the B-cell surface antigen, CD40, by its cognate T-cell ligand

60 Immunohistochemistry was performed for cell surface antigens (CD68 for macrophages, CD4 for lym

61 lls coexpression vectors containing cDNAs of cell surface antigen CD7 and either RAR alpha, RAR beta,

62 d that has grown to include soluble markers, cell-surface antigens, cell-cycle-related proteins, and

63 rologic syndromes and the discovery of novel cell surface antigen central nervous system autoimmune s

64 c differentiation, with both morphologic and cell-surface antigen changes, as well as resistance both

65 eta2m in peptide-based vaccines may increase cell surface antigen densities above thresholds that all

66 We analyzed the expression of various cell surface antigens during a 30-day period after the d

67 e, including one that disrupted the putative cell surface antigen encoding gene, sca1 considered to b

68 tion against a cocktail containing bacterial cell-surface antigens enhanced disease severity as teste

69 l tumors show that the antibody recognizes a cell surface antigen expressed by the majority of colore

70 brane antigen (PSMA) is a well-characterized cell surface antigen expressed by virtually all prostate

71 opulations, is frequently accomplished using cell surface antigens expressed by the cells of interest

72 ion of immunoglobulin G antibodies targeting cell surface antigens expressed in multiple cGVHD affect

73 lls label free using the specific binding of cell surface antigens expressed on the surface of cancer

74 Prostate stem-cell antigen (PSCA) is a cell-surface antigen expressed in normal prostate and ov

75 produce monoclonal antibodies that recognize cell-surface antigens expressed by hematopoietic precurs

76 and immunocytochemical characterization of a cell surface antigen, expressed on globose basal cells (

77 bacterial probiotic cocktail VSL#3 to alter cell surface antigen expression and cytokine production

78 stem cells into clinical applications, their cell surface antigen expression and its chemical structu

79 edly inhibited IL-4-mediated mitogenesis and cell surface antigen expression and was not tyrosine pho

80 We used flow cytometry to characterize cell surface antigen expression on human testicular cell

81 EPCs are generally identified by cell surface antigen expression or counting in a commerc

82 Bronchoalveolar cell profiles, cell surface antigen expression, and superoxide anion pr

83 nd purified subpopulations were assessed for cell surface antigen expression, morphology, and functio

84 d by magnetic bead selection on the basis of cell surface antigen expression.

85 t contamination by exploiting differences in cell surface antigen expression.

86 c probes for PET that are based on targeting cell surface antigen expression.

87 Identification of cell-surface antigen expression associated with hematopo

88 y and on completion of treatment, lymphocyte cell-surface antigen expression was determined by flow c

89 Cell-surface antigen expression was restricted to primar

90 l to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can

91 CD34(++)CD45(low) cells express many cell surface antigens found on multipotent primitive hem

92 In addition, this B-cell surface antigen has been shown recently to be an ef

93 In recent years, novel specific cell surface antigens have allowed identification of leu

94 arious mature blood lineages, a diversity of cell surface antigens have also been specifically recogn

95 Radiolabeled antibodies directed against B-cell surface antigens have emerged as effective and safe

96 cancer, monoclonal antibodies (mAbs) against cell surface antigens have not lived up to their initial

97 tment of Gaucher disease, and a small murine cell surface antigen (heat-stable antigen [HSA]) as a se

98 iral surface: one directed against the human cell surface antigen Her2neu, which belongs to the epide

99 n with monoclonal antibodies that react with cell-surface antigens, however, the protein A-envelope c

100 veloped for characterizing the expression of cell surface antigens, identifies RMEC as a population s

101 45 isoforms is that they interact with other cell surface antigens important in TCR signaling, alteri

102 of lymphopoiesis-related genes and lymphoid cell-surface antigens in LEF1high patients.

103 ntra-exonic recombination in a key family of cell-surface antigens in P. falciparum and thus likely f

104 Cell surface antigens, in addition to HLA, may serve as

105 antibodies (mainly IgG1) against a neuronal cell-surface antigen; in three patients antibodies were

106 pecific antibodies of different valencies to cell surface antigens including MET and EGF receptor, we

107 a suggest that vaccination against bacterial cell-surface antigens increases disease severity, but va

108 ferentiation, such as expression of specific cell surface antigens, inhibition of cell proliferation,

109 self-antigens, we sequestered a tolerogenic cell surface antigen intracellularly by addition of a tw

110 The CD34 cell surface antigen is a glycoprotein expressed by hema

111 The CD20 cell surface antigen is expressed at high levels by over

112 One such cell surface antigen is the ganglioside GD2.

113 The identification of tumor-specific cell surface antigens is a critical step toward the deve

114 The identification of cell surface antigens is critical to the development of

115 The identification of cell surface antigens is critical to the development of

116 conventional targeting against up-regulated cell surface antigens is limited by heterogeneity in exp

117 CA), a homologue of the Ly-6/Thy-1 family of cell surface antigens, is expressed by a majority of hum

118 which is manifested by the expression of the cell surface antigen known as epithelial cell adhesion m

119 A 62-kDa cell surface antigen (M9) of Mycoplasma gallisepticum PG

120 agen type IV), suggesting that the parasitic cell surface antigen may function as an adhesin.

121 Antibody binding to these cell surface antigens may lead to valve damage in rheuma

122 eir living donors and estimated all possible cell surface antigens mismatches for a given donor/recip

123 ed rat monoclonal antibodies (MoAbs) against cell surface antigens of the mouse endothelioma cell lin

124 Using F(ab')2 fragments against a unique cell surface antigen on ACT cells (Thy1.1) or an enginee

125 0-month-old NZB splenocytes recognized pre-B cell surface antigens on both pre-B cell lines and on IL

126 onoclonal antibodies (mAbs) directed against cell-surface antigens on human hematopoietic cells combi

127 it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients

128 is caused by autoantibodies directed against cell-surface antigens on keratinocytes, which when targe

129 e cells without purification on the basis of cell-surface antigens or anatomic location.

130 MN is a novel cell surface antigen originally detected in human HeLa c

131 ediators of tumor-driven angiogenesis, and B cell surface antigens other than CD20.

132 uestration molecules, and the major secreted cell surface antigen p57 (also known as major soluble an

133 ck flagella (flaA, flaB, and flbA) or common cell surface antigen (peb1A) were constructed in strain

134 olic bioavailability in DCs without altering cell-surface antigens, potentially making it a more pote

135 CD5 and CD6, two type I cell surface antigens predominantly expressed by T cells

136 an AML stem cells involves first identifying cell surface antigens preferentially expressed on AML LS

137 clonal antibody (MoAb) that binds to a novel cell surface antigen present on a CD34(bright) subset of

138 The identification of novel cell surface antigens present on tumor cells is crucial

139 howed that these inhibitors induce increased cell-surface antigen presentation of transfected and end

140 f cells characterized by CD44(+)/CD24(-/low) cell-surface antigen profile that have high tumor-initia

141 eptor zeta chain, and upon ligation of their cell-surface antigen receptor overproduce tyrosine phosp

142 in vivo to adjust the signaling threshold of cell surface antigen receptors.

143 ial molecular link between the triggering of cell-surface antigen receptors and nuclear factor kappaB

144 T cells are activated by interaction of cell-surface antigen receptors with major histocompatibi

145 cate that AC133-2, not AC133-1, has been the cell surface antigen recognized by anti-AC133 monoclonal

146 nitor cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+

147 sing with CPD-MAGE-A3 did not alter specific cell-surface antigens required for T-cell activation.

148 O-Glycosylation of CD43, a cell surface antigen rich in O-glycans, was drastically

149 previously described hematopoietic or other cell surface antigen(s).

150 e family (mip-1beta and a tca3 homologue), a cell surface antigen sca-2 and the transcription factor

151 Here we report that the cell surface antigen sca4 of Rickettsia co-localizes wit

152 cines against GD2 (and possibly other cancer cell surface antigens) should be used exclusively in the

153 re differentiation digests an immunodominant cell surface antigen (SOWgp) and prevents host recogniti

154 ified an mAb that is capable of binding to a cell surface antigen specifically expressed on both andr

155 eted in 30 min, and extra time is needed for cell surface antigen staining.

156 Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ga

157 t, to the high cancer-specific expression of cell surface antigens such as mesothelin, which is overe

158 creening of antibody libraries against other cell surface antigens, such as transmembrane receptors,

159 ies but had no effect on antibodies to other cell surface antigens, suggesting that GIF specifically

160 d by malignant plasma cells that express the cell surface antigen syndecan-1 (CD138); however, CD138

161 These approaches aim at myeloma cell surface antigens, T-cell immunity, and biological m

162 All patients had antibodies against neuronal cell surface antigens that by immunoprecipitation were f

163 Activation induces changes in T-cell surface antigens that may distinguish previously st

164 reater attention was given to genes encoding cell surface antigens that were selectively up-regulated

165 number provides the functional diversity of cell surface antigens that, in fungi and other pathogens

166 hymus to reconstitute T cells expressing CD4 cell-surface antigens that are lost during HIV infection

167 antibodies, each corresponding to a specific cell-surface antigen, that have been functionalized in a

168 Once bound to the target cell-surface antigen, the conjugate must be processed to

169 HSCT serum antibodies and subsequently B-CLL cell-surface antigens they recognize, we generated a hum

170 ection through vaccination against bacterial cell-surface antigens; thus far all have failed.

171 s is in accord with the presence of a common cell-surface antigen (TLA antigen) and similarities in t

172 r microarray can be used to screen red blood cell surface antigens using whole blood in a label-free

173 s, transcribes gene units encoding the major cell surface antigens variant surface glycoprotein and p

174 se) increases in cells, the stability of the cell surface antigen VlsE, which presumably did not evol

175 g of antibody fragments (Fabs) reactive with cell surface antigens was established and used to identi

176 ith brain immunohistochemistry optimized for cell-surface antigens was performed.

177 [PfRh2], MSP-119, and the infected red blood cell surface antigens were not.

178 oclonal antibodies raised against epithelial cell-surface antigens were screened for antigen expressi

179 es and cell-based assays with known neuronal cell-surface antigens were used.

180 In contrast to cell surface antigen, which causes the deletion of autor

181 uman cell lines efficiently by targeting the cell surface antigens with antibody-coated beads.

182 Cell surface antigens with highly restricted expression

183 on monoclonal antibodies (mAbs) that target cell surface antigens with restricted expression in pedi

184 ll therapy is limited by the availability of cell surface antigens with sufficient cancer-specific ex

185 the tropism of adenovirus vectors to unique cell surface antigens would be an important development

186 bias, together with polyvalent attachment to cell surface antigen, would ensure that the IgM pentamer